NextCure Interest Expense 2011-2026 | NXTC

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense NextCure

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
1.77 M	4.09 M	4.91 M	1.18 M	1.38 M	183 K	209 K	25 K	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
4.91 M	25 K	1.72 M

Quarterly Interest Expense NextCure

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
321 K	484 K	646 K	-	955 K	1.09 M	1.2 M	-	1.32 M	1.3 M	975 K	-	328 K	208 K	169 K	-	578 K	-35 K	701 K	-	1.03 M	1.29 M	1.52 M	-	56 K	57 K	42 K	-	7 K	6 K	7 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
1.52 M	-35 K	594 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Heron Therapeutics HRTX	1.34 M	$ 0.8	2.7 %	$ 133 M	USA
Amphastar Pharmaceuticals AMPH	23 K	$ 19.23	-1.38 %	$ 899 M	USA
Altimmune ALT	-190 K	$ 3.44	2.99 %	$ 303 M	USA
Aytu BioScience AYTU	-512 K	$ 2.63	0.77 %	$ 16.5 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Ascendis Pharma A/S ASND	80.6 M	$ 218.06	-1.72 %	$ 5 B	Danmark
Incyte Corporation INCY	25.1 M	$ 90.45	-0.36 %	$ 17.7 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Inovio Pharmaceuticals INO	1.22 M	$ 1.61	1.9 %	$ 35.7 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
Inventiva S.A. IVA	12.2 M	$ 6.08	5.19 %	$ 138 M	France
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Cullinan Management CGEM	-443 K	$ 12.84	0.78 %	$ 774 M	USA
Atreca BCEL	3 K	-	-11.76 %	$ 5.79 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
KalVista Pharmaceuticals KALV	4.81 M	$ 16.6	-2.35 %	$ 824 M	Britain
Calithera Biosciences CALA	2.65 M	-	-10.95 %	$ 876 K	USA
Cara Therapeutics CARA	3.59 M	-	-3.03 %	$ 260 M	USA
ChemoCentryx CCXI	2.7 M	-	-	$ 3.74 B	USA
Karyopharm Therapeutics KPTI	28.4 M	$ 6.66	-12.71 %	$ 812 K	USA
Keros Therapeutics KROS	-539 K	$ 11.24	2.55 %	$ 418 M	USA
Checkpoint Therapeutics CKPT	344 K	-	-	$ 169 M	USA
Clovis Oncology CLVS	444 K	-	-7.23 %	$ 13 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Longeveron LGVN	680 K	$ 0.95	-2.71 %	$ 16.7 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Arbutus Biopharma Corporation ABUS	459 K	$ 4.42	4.25 %	$ 734 M	Canada
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA